Search

Search Constraints

You searched for: Author/Creator Lopez-Gitlitz, A

Search Results

1. 200PApalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. (24th November 2019)

2. 213OEfficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. (25th November 2018)

3. 804PHealth-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). (23rd October 2018)

4. 851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). (1st October 2019)

5. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. (27th September 2019)